Ophthalmic CRO unifies clinical environment with Veeva

By Staff reporter

- Last updated on GMT

(Image: Getty/Rawpixel)
(Image: Getty/Rawpixel)
Ora, Inc., an MA-based ophthalmic contract research organization (CRO), has adopted the Veeva Vault Clinical Suite to streamline clinical operations.

The CRO provides preclinical and clinical development services to the ophthalmic drug, drug delivery, and medical devices industries.

To improve visibility throughout its clinical trials, the company has brought together its clinical trial management system (CTMS), electronic trial master file (eTMF), and study start-up applications under the Veeva Vault Clinical Suite​.

“Our partnership with Veeva began well over a year ago when we first implemented Veeva Vault eTMF,"​ explained Edward Leftin, manager of clinical information systems at Ora.

"We then started adding on various clinical and regulatory applications with the latest addition being Veeva Vault CTMS. Ora needed these various system applications, but we also needed a full clinical platform that could scale with our growing organization,"​ he told us.

According to the company, the transition will help its clinical teams manage documents and processes in real-time to improve inspection readiness and accelerate study timelines.

“With Veeva Vault Clinical Suite, we are now able to share trial documents and data in real time with our clients, plus deliver up-to-minute reports and metrics, regardless of where we are in the trial or where the information originated from,"​ added Leftin.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more